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Ovaries and Female Phenotype in a Girl
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A girl with a prenatal 46,XY karyotypewas bornwith a completely normal female phenotype, including uterus and histologically normal
ovaries. In mice with a similar phenotype, the ablation of M33, an ortholog of Drosophila Polycomb, causes male-to-female sex reversal.
The analysis of the human homolog of M33, Chromobox homolog 2 (CBX2), in this girl revealed loss-of-function mutations that al-
lowed us, by placing CBX2 upstream of SRY, to add an additional component to the still incomplete cascade of human sex development.Factors involved in sexual development were ﬁrst deduced
from animal models and from case studies of people whose
genetic or gonadal sex does not match the phenotypic sex.
Despite considerable progress in understanding the
genetic basis of human sexual development, a speciﬁc
molecular diagnosis is identiﬁed in only 20% of disorders
of sex development (DSD)1 cases. Although SRY, the
mammalian sex-determining gene on the Y chromosome
(MIM 480000), is considered to be a master switch for
testicular differentiation, its presence is insufﬁcient to
induce testicular development.2 Several other components
of the male pathway have been identiﬁed, including
Sox9,3 Dmrt1,4 Fgf9,5 Dhh,6 Sox8,7 and Dax1.8 WNT4
appears to be essential for sexual differentiation in
women.9 An additional player was identiﬁed when in
mice targeted ablation of M33, an ortholog of Drosophila
Polycomb,10,11 caused male-to-female sex reversal.12 Apart
from sterility, 50%–75% of M33 knockout Sry-positive
mice were phenotypically perfect females (ovaries with
follicles, uterus, and normal external genitalia). We identi-
ﬁed the human counterpart of this murine model in a girl,
born at term (weight: 3.55 kg, length 54 cm) after an
uneventful pregnancy with no sign of intrauterine growth
retardation, who presented at birth with normal female
external genitalia, despite prenatally determined 46,XY
karyotype. Abdominal ultrasound showed normal uterus.
She is at present the only child of the family.
The 46,XY karyotype, performed prenatally because of
the maternal age, was conﬁrmed postnatally. The karyo-
type in PBLwas analyzed twice, as routinely done in a certi-
ﬁed medical genetic laboratory in at least 100 mitosis. It is
therefore unlikely that a chimerism is present.
Anti-Muellerian hormone was undetectable and basal
testosterone was low (<0.03 ng/ml at age 2 years) and
failed to increase after hCG stimulation (<0.03 ng/ml at
age 2 years). FSH levels were repeatedly elevated (age 1 1/2
years, 60.9 IU/l; age 3 1/2 years, 53.4 IU/l; age 4 10/12
years, 31.1 IU/l), whereas LH levels stayed always normal
(age 3 5/12 years, 1.8 IU/l; age 4 10/12 years, 0.9 IU/l).658 The American Journal of Human Genetics 84, 658–663, May 15No clinical signs of adrenal insufﬁciency were present
and basal plasma cortisol as well as electrolytes were
repeatedly normal (168, 121 ng/ml).
Laparascopy was performed at age 4 1/2 years to evaluate
and potentially remove the gonads. Surprisingly, both
gonads appeared macroscopically as normal ovaries and
were both biopsied. Histology revealed normal ovarian
tissues with primordial follicles (Figure 1A). Vaginoscopy
showed a normal 7.5 cm vagina and a normally appearing
cervix. The study conformed to the guidelines of the insti-
tutional review board.
After obtaining informed consent, genomic DNAwas ex-
tracted fromperipheral blood leukocytes via theDNAblood
and cell culture kit (QIAGEN) and used to perform poly-
merase chain reaction (PCR) exonic ampliﬁcations. SRY
ampliﬁcation was conducted as described.13 The two vari-
ants of CBX2 (MIM 602770), the human homolog of M33
(isoforms 1 and 2, NM_005189.1 and NM_032647.2), are
located on chromosome 17q25 and share the ﬁrst 3 exons
andwere distinguished on the base of size for the ampliﬁca-
tion products containing exon 4, whereas PCR products
generated by using exon 5 primers were speciﬁc for isoform
1 (Figure 1B). DNA from 160 unrelated individuals (120
white, 10 of whom were from Turkey; 20 Asian; 20 blacks)
was used as controls (320 chromosomes; power > 80%
according to Collins & Schwartz14). The coding region of
SOX9 (NC_00017.9; MIM 608160; MIM 114290) was also
analyzed. SF1/NR5A1 (MIM 184757) was investigated as
described.15 The PCR products were sequenced with the
Big Dye Terminator Cycle Sequencing Kit and analyzed on
an ABI Prism 310 Genetic Analyzer (Applied Biosystems).
Primer sequences available in the Supplemental Data avail-
able online.
Direct sequencing of the CBX2 gene of the patient re-
vealed the presence of a C to T exchange (c.C293T) and
a G to C exchange both in exon 5 (c.G1370C) and both
in the heterozygote state, leading to P98L (inherited from
the father) and R443P (inherited from the mother) muta-
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Figure 1. Ovarian Phenotype, Genotype, and Genotyping Strategy
(A) Hystology of bioptic ovarian fragment (0.3 3 0.2 3 0.15 cm) showing ovarian cortex stromal tissue and two primordial follicles.
(B) DNA sequence chromatograms obtained by direct sequencing of PCR products showing the presence of the heterozygote c.C293T and
c.G1370C substitution in exon 5, not present in normal individuals (control, representative example out of 320 alleles).
(C) General structure of the CBX2 gene and protein variants and location of the P98L and R443Pmutations. Exons are represented by boxes.
The PCR products and their lengths are also depicted: black lines, products common to both variants; blue line, product of variant 2 only;
yellow lines, products of variant 1 only. The protein domains were identified with the SMART server. Abbreviations: CHROMO, CHRomatin
Organization mOdifier; ATT-hook, small DNA binding motif originally described in the high-mobility group (HMG) nonhistone chromosomal
protein HMG-I; SPT2, S. cerevisiae chromatin protein involved in transcriptional regulation; FN3, fibronectin 3-repeat region; LRR_R1,
leucin-repeat region involved in protein-protein interaction; HMG17, high mobility group nonhistone chromatin component.absence in 320 alleles of 160 unrelated individuals sug-
gested that they are not common polymorphisms. SRY
was normal. We excluded SOX9 and SF1/NR5A1mutations
and DAX1/NR0B1 duplication, the other possible molec-
ular causes of a similar phenotype. The mutated amino
acid residues P98 and R463 are conserved in the mouse
protein, and P98 lies in a region with similarity to the yeast
SPT2 protein, a chromatin binding protein involved in
transcriptional regulation (Figure 1C). Proline is an
alpha-helix disruptor, so its substitution with a lysine at
98 and its introduction at 443 is likely to change the
three-dimensional structure of the protein.
After PCR-mediated addition of an N-terminal myc tag,
the CBX2 cDNA, obtained by Origene (Trueclone
TC303599, Origene Australia) was inserted into a pCMV6
vector. Mutant cDNAs were constructed with the Quik-
Change II site-directed mutagenesis kit from Stratagene.
Introduction of the mutations was conﬁrmed by
sequencing. Wild-type, mutants, and a 1:1 combination of
both cDNAs were transfected into 5 3 104 cells of the
following cell lines: HepG2 (ATCC HB-8065); NT2-D1
(ICLC HTL97025), and NCI-H295 (ATCC-2128, a generous
gift of William Rainey, University of Texas Southwestern,The AmDallas, TX). These cell lines expressed the main factors
essential for a proper sex development with different
patterns (details available upon request). The cells were
initially seeded in their optimum medium, let grow to
80%–90% conﬂuence, and then transfected with wild-type
and/or mutant cDNA with TransFast transfection reagent
(Promega; 9 ml transfection reagent/mg DNA/plate). Trans-
fection efﬁciency was monitored by cotransfection with
a b-galactosidase expression plasmid (Promega pSV-b-galac-
tosidase control vector, molar ratio CBX2: b-gal ¼ 2:1).
Transfection efﬁciency was 40%–60%. 48 hr after transfec-
tion RNAwas extracted with the RNeasy kit (QIAGEN).
Western blot analysis was performed according to stan-
dard procedures and with polyclonal goat antihuman-
CBX2/M33 antibodies (EB07432, Everest Biotech, Oxford,
UK) or an antibody against themyc epitope (9E10, dilution
1:100).
Western blot suggested that there are no signiﬁcant
differences in protein synthesis or stability between WT
and mutant CBX2 (not shown).
In the RNA interference experiments, two of the tested
siRNAs (designed with the Promega siRNADesigner
program) proved, after optimization, to efﬁciently blockerican Journal of Human Genetics 84, 658–663, May 15, 2009 659
Figure 2. Binding of CBX2 to SF1/
NR5A1 Promoter and Influence on
Expression
(A) Role of CBX2 variants on the expression
of the putative target gene SF1/NR5A1 and
proof of a direct influence of CBX2 by its
direct binding to promoter target sequences.
Expression of SF1 in H295R cells nontrans-
fected (control) or transfected with WT or
mutant CBX2.
(B–D) Qualitative (B) and quantitative (C)
chromatine immunoprecipitation (ChIP)
assay. Crosslinked extracts from H295R cells
with or without transfection with WT or
mutated CBX2 were sonicated and immuno-
precipitated with anti-myc (tag) antibody.
After reverse cross-linking, PCR was per-
formed with primers specific for the regions
depicted in (D). The numbers on top of the
gel in (B) correspond to fragment numbers .
Quantitative RT-PCR was performed with
SYBR Green incorporation. The data are
expressed as mean5 SD.the endogenous and the exogenous (transfected) CBX2
expression in OvCar3 cells. These two siRNAs (Ambion)
designated siRNA1 (mRNA 145-164) and siRNA2 (411-430)
were used in combination at the concentration of 75 pmol
each. Scramble siRNAs were used as control. In 24-well
plates, 5 3 103 NT2-D1 cells/well were cultured in DMEM
medium for 48 hr until they reached 50% conﬂuence. The
siRNAs were then transfected with Lipofectamine 2000 (In-
vitrogen) as suggested by the provider. 48 hr later, RNA was
extracted with RNeasyminikit (QIAGEN) and used for qual-
itative reverse transcriptase PCR and quantitative real-time
PCR. The inﬂuence of CBX2 on the expression of SRY (acc
no. NM_0031401), SF1/NR5A1 (NM_004959), and SOX9
(BC056420) was studied by means of quantitative real-
time PCR, performed with an ABI 7000 Sequence Detection
System (Applera Europe) and PCR products were quantiﬁed
ﬂuorometrically with the SYBRGreen Core Reagent kit. The
reference mRNA cyclophillin was used for normalizing the
data (primers sequence available in Supplemental Data).
Western blot was performed as above.
Downregulation of CBX2 obtained by siRNA treatment
signiﬁcantly reduced expression of the putative targets
(Figure S1) supporting the CBX2-dependent expression of
these genes.
Chromatin immunoprecipitation (ChIP) was performed
with the protocol described by Katoh-Fukui et al.,16 except
for the human SF1/NR5A1 (NG_008176)-speciﬁc primers
used for PCR (available in Supplemental Data) and for the
usage of H295R cells. PCR conditions were validated with
genomic DNA as template. Anti-myc antibodies (9E10) that
recognize only the transfectedCBX2were used for immuno-
precipitation (IP). After optimization, ﬁve fragments were
found to be the most suitable: fragment 1 (324 bp) from
465 to 85, fragment 2 (651 bp) from 85 to þ 524 con-660 The American Journal of Human Genetics 84, 658–663, May 15taining the noncoding ﬁrst exon, fragment 3 (171 bp)
from þ239 to þ 410, fragment 4 (767 bp) from 1232 to
465, and fragment 5 (920 bp) from 8761 to 9681 encom-
passing exon 2. Fragment 5 was not ampliﬁed after IP
enrichment and was used for control (background). Two
fragments ampliﬁed from genes ﬂanking SF1/NR5A1 on
chromosome 9q33, GPR144 and NR6A1, were used as
control for unspeciﬁc enrichment. Starting DNA amounts
were determined by optical density (OD 260 nm). For the
quantitative real-time PCR assays, all samples were run in
triplicate with the SYBR Green Core Reagent kit with the
immunoprecipitate DNA samples (experiment) run in
parallel with their INPUT counterparts. Average cycle
threshold (Ct) of INPUT was subtracted from the experi-
ment average Ct to give the CtNET. Cts derived from the
control fragment (nontargetDNA), namedCtCTRLwere sub-
tracted fromtheCtNET toobtain thedeﬁnitiveCt. Thedeﬁn-
itive Cts of three independent experiments were plotted
as multiple of the value of nontransfected cells set as 1
(mean5 SD ; no DNA¼ 0) and represent fold enrichment.
Real-time PCR experiments showed that in H295R WT
CBX2 increased 6-fold the expression of endogenous SF1/
NR5A1. With the two mutated CBX2 proteins, the effect
signiﬁcantly diminished (Figure 2A). To verify a direct
inﬂuence of CBX2 on SF1 transcription, ChIP experiments
were carried out. Whereas WT CBX2 transfected in H295R
cells caused enrichment of three fragments corresponding
to sequences in the SF1/NR5A1 promoter, mutant CBX2s
failed to bind to one of the fragments, which contains
the noncoding ﬁrst exon (fragment 2). These results are
conﬁrmed in the quantitative ChIP experiments (Figures
2B and 2C).
In silico search for possible Polycomb responsive
elements (PRE) was carried out with GeneACT potential, 2009
Figure 3. Effect of CBX2 Variants on
Gene Target Promoters
(A) Transactivation of luciferase reporter
driven by deletion construct of SF1
promoter in absence (0) or presence of over-
expression of WT or both CBX2 mutants
(PþL). Luciferase activity is expressed as
relative to empty vector (luc). Construct
þ524/85 scr/inv contains the same
sequence as in 85/þ524 that was scram-
bled and inserted in the opposite direction.
For reference to the ChIP experiments,
construct 465/þ524 contains ChIP frag-
ments 1, 2, and 3; 85/þ524 is fragment
2 and contains fragment 3; þ239/þ524
contains fragment 3.
(B) Real-time PCR of endogenous SF1 in
H295R without (0) or with transfection of
wild-type (WT) or mutant CBX2. The image
represents the results of mean 5 SD of
three independent experiments.
The comparison between (A) and (B)
suggests that the stimulatory effect of WT
CBX2 on the 85/þ524 sequence is domi-
nant over the inhibitory effect of the bigger
construct (465/þ524).binding sites online facility with PRE/TRE motifs17,18 as
possible binding site sequences.
Three different constructs containing fragments of the
SF1 promoter upstream of a ﬁreﬂy luciferase reporter (in
pGL4, Promega), a kind gift of Serdar E. Bulun (Northwest
University, Chicago, IL), were used as a putative target for
CBX2. The constructs encompass sequence 465/þ524
relative to the start site of transcription (NG_008176
4563-5550), 85/þ524, and þ 293/þ524, respectively.19
The two longest constructs contain the ﬁrst noncoding
SF1/NR5A1 exon. The fragment 85/þ524 was scrambled
and inserted in the pGL4 vector in the inverse direction
by substituting KpnI with EcoRV on the direct primer
(85 GATATCGTGGGGGCAGAGACCAAT) and vice versa
on the reverse primer (þ524 GGTACCAGAGAGAGCCAC
AGAGACAAC). This experiment substituted the classical
site-directed mutagenesis, because of the lack of clear poly-
comb recognition sites in our sequence of interest.
3 3 103 H295R or HepG2 cells were seeded in 24-well
plates and let grow to 60% conﬂuence. These cell lines
were chosen because of the expression of SF1/NR5A1 in
both and of CBX2 in one (H295R) and not in the other
(HepG2). After optimization, a 2:1 reporter:CBX2 plus 1/20
Renilla luciferase (pRL-SV40) construct mixture (total 5 mg
DNA/well) was added to a 6-fold FuGene (Roche) and
used for transfection. Mock transfection was used as basal
(0) level. The empty vector pGL3 was used as internal
negative control. 48 hr after transfection, cells were
prepared for the Dual-Luciferase Reporter Assay (Promega).
Relative luciferase units (Fireﬂy/Renilla) were obtained
with a Lumat 9017 luminometer (Berthold Technologies).The AmTo assess the effect of CBX2 directly on transcription, we
assayed transactivation of a luciferase reporter driven by
deletion constructs of the SF1 promoter.19 The longest
construct (465/þ524) contains ChIP fragments 1, 2,
and 3; the 85/þ524 construct is fragment 2 and encom-
passes fragment 3; and construct þ239/þ524 contains
fragment 3 (Figure 2D). Wild-type CBX2 had an inhibitory
effect on the 465/þ524 construct, a stimulatory effect on
the 85/þ524, and no effect on the shorter construct in
transfected H295R cells (Figure 3A). That hints to the
presence of a negative regulatory element between 465
and 85 and of an activating element between 85
and þ 239, the latter being dominant over the former, as
indicated by the fact that overexpression of WT CBX2
increases SF1 mRNA in quantitative RT-PCR experiments
(Figures 2A and 3B). CBX2 mutants were signiﬁcantly
less efﬁcient in stimulating luciferase expression when
the 85/þ524 construct was used. This sequence is the
ChIP fragment that the mutant CBX2 failed to bind (frag-
ment 2). The insertion of the same scrambled sequence in
the inverse direction abolished all these differences, indi-
cating that the effect is speciﬁc (Figure 3A). The differences
in luciferase activity betweenWTandmutant CBX2 for the
other two constructs were not signiﬁcant.
The present case indicates that CBX2 might now be
added to the list of genes involved in the molecular path-
ogenesis of DSD. As in the mouse model, it appears that
CBX2 is upstream of SRY in the sex determination cascade
in humans, and its deﬁciency represents an autosomal-
recessive cause of 46,XY DSD. That CBX2 stimulates
expression of target genes (SF1/NR5A1) is in agreementerican Journal of Human Genetics 84, 658–663, May 15, 2009 661
with previous data,16 but in contrast to the dogma that
polycomb proteins are silencing factors.20 However, some
examples have emerged in which polycomb proteins are
stimulators of transcription in Drosophila21–23 and in
mouse,24 showing that there may be exceptions to
the rule. As elegantly discussed by Katoh-Fukui and
coworkers,16 CBX2 might have a role (as transactivator)
distinct from its known function as chromatin modiﬁer.
Accordingly, our experiments suggest a possible model in
which normal CBX2 acts preferentially on regions of the
promoter of the representative target gene SF1/NR5A1
that are related to activation of transcription. The mutants
bind to a different sequence with consequent lack of stim-
ulation. Future studies should establish whether these
differences are due to differences in interaction with the
partners in the PRC1 complex.
In contrast to the mouse, human skeletal development,
adrenal, and splenic growth do not seem to be grossly
inﬂuenced by these CBX2 mutations. This suggests the
presence of alternative pathways or functions for CBX2
in humans. Targeted speciﬁc knockin animal experiments
might provide means for the direct comparison between
human and mouse phenotypes.
Our case was discovered because the prenatal karyotype
and the phenotype at birth were discrepant. In contrast to
most cases of 46,XY DSD, this girl had normal female
internal and external genitalia and, more importantly,
instead of dysgenetic gonads, normal bilateral ovaries at
histology. Our observations might be important for
ovarian development as well as for male sexual differentia-
tion. CBX2 seems to function by actively repressing
ovarian development in XY gonads, because mutations
in this gene cause male-to-female sex reversal with ovaries
in SRY-positive mice12 and humans (present work). As sug-
gested by preliminary data, CBX2 might inﬂuence sex
differentiation by regulating SRY expression directly or
via other factors such as WT1 (unpublished data).
Although generalization should await the description of
additional cases, the identiﬁcation of such cases might be
difﬁcult, given the completely normal female phenotype.
Given the young age of our patient, even the high FSH
levels cannot reﬂect accurately the potential for pubertal
function and fertility. If the similarity between mouse
and human phenotype remains throughout life, unex-
plained sterility in women might be a unique sign of
CBX2 abnormalities in the human population.
Supplemental Data
Supplemental Data include one ﬁgure and three tables and can be
found with this article online at http://www.ajhg.org/.
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